Alteplase for treating acute ischaemic stroke

be started as early as possible within 4.5 hours after onset of stroke symptoms and after exclusion of intracranial haemorrhage by appropriate imaging techniques. 2.2 The summary of product characteristics lists the following adverse reactions for alteplase: haemorrhage (intracranial and gastrointestinal), recurrent ischaemia or angina, hypotension, heart failure, pulmonary oedema and reperfusion arrhythmias. For full details of adverse reactions and contraindications, see the summary of product characteristics. 2.3 The cost of alteplase is £135 per 10-mg pack, £180 per 20-mg pack and £300 per 50-mg pack (excluding VAT; BNF edition 63). The cost per course of treatment depends on the body weight of the patient, and can range from £300 to £600 based on a recommended dose of 0.9 mg per kilogram of body weight. Costs may vary in different settings because of negotiated procurement discounts. Alteplase for treating acute ischaemic stroke (TA264) 3 The manufacturer's submission 3.1 The Appraisal Committee considered evidence submitted by the manufacturer of alteplase and a review of this submission by the Evidence Review Group (ERG). The decision problem addressed by the manufacturer considered whether treatment with alteplase was clinically effective compared with standard medical care (standard medical and supportive management that does not include
